Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | £854,106 | £1,135,686 | £1,168,674 | £675,467 |
| Short-Term Investments | £200,000 | £166,252 | £108,075 | £0 |
| Receivables | £4,018,009 | £3,369,996 | £2,963,144 | £3,347,781 |
| Inventory | £13,014,795 | £13,472,546 | £11,573,485 | £7,804,586 |
| Other Curr. Assets | £2,730,675 | £2,731,375 | £2,605,881 | £1,943,012 |
| Total Curr. Assets | £20,817,584 | £20,875,854 | £18,419,258 | £13,770,846 |
| Property Plant & Equip (Net) | £43,049,308 | £42,807,839 | £42,379,222 | £36,531,260 |
| Goodwill | £674,570 | £674,570 | £674,570 | £546,691 |
| Intangibles | £4,720,697 | £4,721,035 | £4,562,988 | £1,380,694 |
| Long-Term Investments | -£179,027 | £20,973 | £23,357 | £16,592 |
| Tax Assets | £60,891 | £0 | £88,640 | -£16,592 |
| Other NC Assets | £200,000 | £56,512 | £0 | £16,592 |
| Total NC Assets | £48,526,439 | £48,280,929 | £47,728,777 | £38,475,238 |
| Other Assets | £0 | £0 | £0 | £0 |
| Total Assets | £69,344,023 | £69,156,783 | £66,148,036 | £52,246,084 |
| Liabilities | – | – | – | – |
| Payables | £3,671,372 | £1,618,272 | £1,373,371 | £769,205 |
| Short-Term Debt | £4,267,459 | £8,061,066 | £8,916,513 | £6,424,587 |
| Tax Payable | £429,267 | £454,087 | £99,449 | £222,506 |
| Deferred Revenue | £0 | £0 | £0 | £368,435 |
| Other Curr. Liab. | £1,193,888 | £3,131,599 | £2,346,599 | £1,564,945 |
| Total Curr. Liab. | £9,561,986 | £13,265,024 | £12,735,932 | £9,349,678 |
| LT Debt | £1,757,971 | £2,550,833 | £3,454,189 | £1,206,717 |
| Deferred Rev, NC | £0 | £0 | £0 | £2,101,237 |
| Deferred Tax Liab, NC | £2,574,582 | £2,550,496 | £2,536,838 | £0 |
| Other NC Liab. | £3,546,580 | £3,170,764 | £2,785,073 | £2,223,587 |
| Total NC Liab. | £7,879,133 | £8,272,093 | £8,776,099 | £5,531,541 |
| Other Liabilities | £0 | £0 | £0 | £0 |
| Cap. Leases | £464,015 | £539,638 | £617,341 | £347,997 |
| Total Liabilities | £17,441,120 | £21,537,117 | £21,512,031 | £14,881,219 |
| Equity | – | – | – | – |
| Pref Stock | £0 | £0 | £0 | £0 |
| Common Stock | £4,461,121 | £4,461,121 | £4,461,121 | £4,461,121 |
| Retained Earnings | £35,079,327 | £30,806,194 | £27,747,886 | £24,179,783 |
| AOCI | £1,450,405 | £1,454,277 | £1,432,379 | £1,430,543 |
| Other Equity | £6,959,112 | £6,959,112 | £6,959,112 | £6,959,112 |
| Total Equity | £47,949,965 | £43,680,704 | £40,600,498 | £37,030,558 |
| Supplemental Information | – | – | – | – |
| Minority Interest | £3,952,938 | £3,938,962 | £4,035,507 | £334,307 |
| Total Liab. & Tot. Equity | £69,344,023 | £69,156,783 | £66,148,036 | £52,246,084 |
| Net Debt | £5,171,325 | £9,476,213 | £11,202,028 | £6,955,838 |